In Re: Aflibercept Patent Litigation
Case Number:
1:24-md-03103
Court:
Nature of Suit:
Multi Party Litigation:
Multi-district Litigation
Judge:
Chief District Judge Thomas S Kleeh
Firms
- Bowles Rice
- Cravath Swaine
- Fish & Richardson
- Flaherty Sensabaugh
- Gemini Law
- Goodwin Procter
- Hendrickson & Long
- Hissam Forman
- Horn Aylward
- Jenner & Block
- Kellogg Hansen
- Marshall Gerstein
- MoloLamken
- Olson Stein
- Paul Weiss
- Proskauer Rose
- Quinn Emanuel
- Rakoczy Molino
- Robinson Miller
- Rothwell Figg
- Schrader Companion
- Steptoe & Johnson PLLC
- Thomas Combs
- Umhofer Mitchell
- Weil Gotshal
- Wilentz Goldman
- Williams & Connolly
- Willkie Farr
Companies
- Amgen Inc.
- Biocon Ltd.
- Regeneron Pharmaceuticals Inc.
- Samsung Electronics Co. Ltd.
- Sandoz International GmbH
- Viatris Inc.
Sectors & Industries:
-
February 12, 2026
Regeneron, Samsung Bioepis Settle Eye Med Patent Claims
Regeneron Pharmaceuticals Inc. and Samsung Bioepis Co. Ltd. have told a West Virginia federal court they reached an agreement to end patent infringement claims brought by Regeneron over a biosimilar of its eye medication Eylea.
-
June 26, 2025
Stewart, APJ Leader Discretionarily Deny 33 More Petitions
The acting U.S. Patent and Trademark Office director rejected 21 petitions for Patent Trial and Appeal Board reviews on Wednesday, and the board's acting deputy chief judge denied another 12 where the acting director recused herself for the first time.
-
April 23, 2025
Judge Lifts Biocon Eye Med Biosimilar Ban After Settlement
A West Virginia federal judge has vacated a permanent injunction that had blocked Biocon Biologics Inc. from selling a biosimilar to Regeneron's blockbuster eye medication Eylea in the U.S., citing a settlement agreement in the patent litigation allowing sales of the biosimilar in 2026.